Literature DB >> 2440105

Tissue distribution and developmental expression of the messenger RNA encoding angiogenin.

H L Weiner, L H Weiner, J L Swain.   

Abstract

New blood vessel growth occurs during normal fetal development and in diseases such as cancer and diabetes. The polypeptide angiogenin induces new blood vessel growth in two biological assays and may play a role in the vascular development of the fetus and in the neovascularization that accompanies diseases and wound healing. A complementary DNA probe for human angiogenin was used to examine the tissue distribution of angiogenin messenger RNA (mRNA) in the developing rat and in selected transformed cell lines. Angiogenin mRNA was detected predominantly in adult liver but was also detectable at low levels in other tissues. The expression of the angiogenin gene in rat liver was found to be developmentally regulated; mRNA levels were low in the developing fetus, increased in the neonate, and maximal in the adult. The amount of angiogenin mRNA in human HT-29 colon carcinoma and SK-HEP hepatoma cells was not greater than that in normal rat liver. These results demonstrate that angiogenin is predominantly expressed in adult liver, that the pattern of angiogenin gene expression is not temporally related to vascular development in the rat, and that the transformed cells studied do not contain more angiogenin mRNA than does normal liver. If angiogenin activity is controlled at the transcriptional level, the results of this study suggest that the primary function of angiogenin in vivo may be in processes other than the regulation of vascular growth.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440105     DOI: 10.1126/science.2440105

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  37 in total

1.  A gender-specific mRNA encoding a cytotoxic ribonuclease contains a 3' UTR of unusual length and structure.

Authors:  S Chen; S Y Le; D L Newton; J V Maizel; S M Rybak
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

2.  A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors. Studies on the effects of carriers, PBS, angiogenin, and bFGF.

Authors:  J Wilting; B Christ; M Bokeloh
Journal:  Anat Embryol (Berl)       Date:  1991

3.  A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation.

Authors:  Norie Yoshioka; Li Wang; Koji Kishimoto; Takanori Tsuji; Guo-fu Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

4.  Specific binding of angiogenin to calf pulmonary artery endothelial cells.

Authors:  J Badet; F Soncin; J D Guitton; O Lamare; T Cartwright; D Barritault
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

5.  Localization of the human angiogenin gene to chromosome band 14q11, proximal to the T cell receptor alpha/delta locus.

Authors:  S Weremowicz; E A Fox; C C Morton; B L Vallee
Journal:  Am J Hum Genet       Date:  1990-12       Impact factor: 11.025

6.  Angiogenin inhibits nuclear translocation of apoptosis inducing factor in a Bcl-2-dependent manner.

Authors:  Shuping Li; Wenhao Yu; Guo-Fu Hu
Journal:  J Cell Physiol       Date:  2012-04       Impact factor: 6.384

7.  Secretion of ribonucleases by normal and immortalized cells grown in serum-free culture conditions.

Authors:  M Moenner; E Hatzi; J Badet
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997 Jul-Aug       Impact factor: 2.416

8.  Angiogenin as a molecular target for the treatment of prostate cancer.

Authors:  Shuping Li; Soichiro Ibaragi; Guo-Fu Hu
Journal:  Curr Cancer Ther Rev       Date:  2011-05

9.  A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice.

Authors:  I J Polakowski; M K Lewis; V R Muthukkaruppan; B Erdman; L Kubai; R Auerbach
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

10.  Tumor angiogenesis: insights and innovations.

Authors:  Fernando Nussenbaum; Ira M Herman
Journal:  J Oncol       Date:  2010-04-26       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.